Health care stocks were flat to lower pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) inactive and the iShares Biotechnology ETF (IBB) down 0.2%.
Argenx (ARGX) stock was nearly 4% higher after the company said a phase 3 study of its drug Vyvgart met its primary endpoint in treating patients with AChR-Ab seronegative generalized myasthenia gravis, an autoimmune disease.
Axogen (AXGN) shares were down more than 10% after the company said the US Food and Drug Administration has extended the review deadline for its marketing application for the Avance Nerve Graft by three months.
BeOne Medicines (ONC) shares were up more than 2% after the company said it has agreed to sell its royalty rights, excluding China, on Amgen's (AMGN) lung cancer drug, Imdelltra, to Royalty Pharma (RPRX) for up to $950 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。